2023年ESMO大会上，阿贝西利联合ET辅助治疗HR+，HER2-早期高危乳腺癌的III期monarchE研究，以及帕博利珠单抗联合化疗新辅助治疗+单药辅助治疗早期三阴性乳腺癌的KEYNOTE-522研究5年随访结果分别正式揭晓。我们一起来看看这两项研究在更长期的时间维度上能为患者带来怎样的获益。monarchE研究：5年长期复发和死亡风险降低32...
1. Merck announces phase 3 KEYNOTE-522 trial met its overall survival (OS) endpoint in patients with high-risk early-stage triple negative breast cancer (TNBC). News release. May 28, 2024. Accessed May 28, 2024. 2. Schmid P, Cortés J, Dent RA, et al. LBA18 Pembrolizumab or placebo...
0:09 | The KEYNOTE-522 trial was designed to look into the benefit of pembrolizumab on top of chemotherapy in patients with stage II and stage III triple-negative breast cancer. Patients were randomized 2:1 to 6 months of preoperative chemotherapy, either with pembrolizumab or with placebo, ...
The KEYNOTE-522 trial is the first randomised phase 3 trial of an immune checkpoint inhibitor in early triple negative breast cancer. We've seen data in metastatic triple negative breast cancer with immune checkpoint inhibitors showing a clear benefit in survival. When it comes to early triple ...
2.https://www.merck.com/news/merck-announces-phase-3-keynote-522-trial-met-dual-primary-endpoint-of-event-free-survival-efs-in-patients-with-high-risk-early-stage-triple-negative-breast-cancer-tnbc/ FYI:总结生物医药更多知识点,敬请关注公众平台「佰傲谷BioValley」 ...
5月13日,默沙东宣布,在治疗高危早期三阴性乳腺癌方面,其抗PD-1疗法Keytruda 在III期 KEYNOTE-522试验中已达EFS临床试验双重主要终点。 数据显示,在此项试验研究中,与单一的新辅助化疗疗法相比,Keytruda采取与化疗在术前进行联合治疗的方法,并在术后作为单药辅助治疗,在临床数据上取得了更好地提升效果。
Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress. Peter Schmid, MD, PhD, of Barts Cancer Institute at Queen Mary University in London, United Kingdom, discusses his key takeaways from the ...
KEYNOTE-522是免疫检查点抑制剂用于早期三阴性乳腺癌新辅助治疗入组病例最多的一项研究,与多数类似早期三阴性乳腺癌研究不同的是,研究组不仅在新辅助化疗时联合应用帕博利珠单抗,而且在术后辅助治疗时继续应用,前后共一年。本研究的重要意义在于...
e12612#Background:Triple-negative breast cancer (TNBC) constitutes approximately 15% of all breast cancers and predominantly affects younger women with a disproportionate impact on Black and Hispanic ethnicities. Historically, neoadjuvant therapy centered around chemotherapy alone. However, the KEYNOTE 522...
2023SABCS 大会聚光灯丨来自KEYNOTE-522 3期研究的最新无事件生存结果 LBO1-02 研究标题: (LBO1-02) Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and...